<DOC>
	<DOCNO>NCT00389779</DOCNO>
	<brief_summary>This randomize , double-blind , placebo- active-controlled study new experimental drug call darusentan . Darusentan currently approve United States Food Drug Administration ( FDA ) , mean doctor prescribe drug . The purpose study determine darusentan effective reduce systolic diastolic hypertension despite treatment full dos three antihypertensive drug , include diuretic . Subjects randomize darusentan ( optimize dose ) , active comparator , placebo , administer orally . The treatment period trial 14 week .</brief_summary>
	<brief_title>DORADO-AC - Optimized Doses Darusentan Compared Active Control Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<mesh_term>LU 135252</mesh_term>
	<criteria>SELECTED INCLUSION CRITERIA : 1 . Subjects competent provide write consent ; 2 . Aged 35 80 year ; 3 . Subjects diabetes and/or chronic kidney disease must average sit systolic blood pressure great equal 130 mmHg ; 4 . All subject must average sit systolic blood pressure great equal 140 mmHg ; 5 . Receiving adhere full dos appropriate guidelinerecommended antihypertensive drug three different class antihypertensive agent , include diuretic ; 6 . Female subject nonchildbearing potential ( i.e. , postmenopausal least 2 year surgically sterile ) . SELECTED EXCLUSION CRITERIA : 1 . Average sit systolic diastolic blood pressure great equal 180 mmHg 110 mmHg , respectively ; 2 . Subjects treated central alpha2 agonist and/or imidazoline receptor agonist ; 3 . Left ventricular dysfunction ; 4 . Serum ALT AST great 2 time Upper Limit Normal ; 5 . Subjects experience myocardial infarction , unstable angina pectoris , cerebrovascular accident within 6 month ; sick sinus syndrome second third degree atrioventricular block , atrial fibrillation recurrent atrial tachycardia , recurrent ventricular tachycardia , symptomatic bradycardia ; 6 . Implanted pacemaker cardioverter defibrillator ; 7 . Symptomatic congestive heart failure require treatment ; 8 . Hemodynamically significant valvular heart disease ; 9 . Hemodialysis peritoneal dialysis , history renal transplant ; 10 . Type I diabetes mellitus ; 11 . Diagnosis recurrence malignancy within past 3 year ; 12 . Sleep apnea , unless recent sleep study demonstrate arterial oxygenation saturation great equal 90 % , treat untreated ; 13 . Subjects perform alternate shift night work ; 14 . Subjects participate clinical study involve another investigational drug device within 4 week prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>